Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb and Pfizer receive draft NICE recommendation for Eliquis

Bristol-Myers Squibb and Pfizer receive draft NICE recommendation for Eliquis

10th March 2015

Bristol-Myers Squibb and Pfizer have received a provisional recommendation for their novel anticoagulant Eliquis to be used in a new indication within the NHS.

The UK's National Institute for Health and Care Excellence (NICE) has published draft guidance endorsing the oral anti-blood clotting drug as an option for treating and preventing venous thromboembolism (VTE) in adults.

Eliquis is given as a tablet and helps to prevent blood from clotting by stopping a substance called Factor Xa – which plays a key role in blood clot formation – from functioning.

It represents an alternative to the long-established warfarin, which can be difficult to use due to the need for frequent tests to see if the blood is clotting properly, and having to adjust the dose if it is not.

Professor Carole Longson, NICE's Health Technology Evaluation Centre director, said the drug offers benefits over warfarin because it "does not require frequent blood tests to monitor treatment and so represents a potential benefit for many people who have had a VTE".

Bristol-Myers Squibb and Pfizer are currently developing an antidote for Eliquis, andexanet alfa, which has been shown to produce rapid and nearly complete reversal of its effects in cases where this is clinically necessary.ADNFCR-8000103-ID-801778955-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.